Transforming women's health
The first non hormonal treatment for women suffering from genitourinary syndrome of menopause.
Genitourinary Syndrome
of Menopause
GSM, also known as vaginal atrophy, is a thinning and inflammation of the vaginal walls that is a consequence of reduced estrogen production. This condition can make it painful just to sit, walk or urinate.
The Revolutionary Device for treating GSM
A treatment that fits in with your daily life. The accessible, safe, and affordable treatment that is suitable for everyone – creating a stronger you.
Santoro,N.F.&LIN,L(2016)
British Society for Sexual Medicine
The North American Menopause Society
Shifren, J. L., & Gass M. L. S., NAMS Recommendations for Clinical Care of Midlife Women Working Group. (2014). The North American Menopause Society recommendations for clinical care of midlife women. Menopause, 21(10), 1-25.
Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey
Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Nappi RE, Kokot-Kierepa M. 2012, Climacteric. pp.15 (1): 36-44.
Journal of womens health
Dahlgren et al (2023). Identifying Variables Associated with Menopause-Related Shame and Stigma: Results from a National Survey Study. Journal of women's health (2002), 32(11), 1182–1191.
Patient Impact
GSM impacts a large number of people around the world, here’s what the research is telling us about our patients.
Milestones Completed to Date
Q3 2020
Intellectual Property (IP) Filed
Q3 2020
Q2 2022
US Institutional Review Board Study Completed
Q2 2023
Functional Prototype Designed
Q2 2023
Q2 2023
Start of First-in-Human Trial
Q2 2024
Identification of Clinical Trial Sites in Europe & US
Q2 2024
Q3 2024
De-risk of Manufacturability and Scaling
Q3 2024
FDA Investigational Device Exemption Granted for Pilot Trial
Q3 2024
Q4 2024
Completion of First-in-Human Trial
Q2 2025
Start of Pilot Trial
Q2 2025